Infectious Disease Phase 1 Deal Benchmarks — US Only (2026)
Median upfront of $91M with total deal values reaching $774M in US Only territory.
Median Upfront
$91M
Total Deal Value
$553M
Royalty Range
4.7%–9.3%
Territory Multiplier
0.55x
Understanding Infectious Disease Deal Benchmarks at Phase 1
Phase 1 Infectious Disease licensing deals in US Only territory command a median upfront payment of $91M, with values ranging from $45M at the low end to $136M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $332M to $774M, with a median of $553M. Royalty rates for infectious disease assets at this stage typically fall between 4.7% and 9.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $45M | $91M | $136M |
| Total Deal Value | $332M | $553M | $774M |
| Royalty Rate | 4.7% | — | 9.3% |
Comparable Deals
No territory-specific comparable deals. Use the calculator for full analysis.
See All Comparable Deals
View 0 comparable Infectious Disease transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Infectious Disease deals in US Only territory?
How does US Only territory affect Infectious Disease deal value?
What royalty rates are typical for Phase 1 Infectious Disease licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$36M upfront
Infectious Disease · Preclinical · US Only
$282M upfront
Infectious Disease · Phase 2 · US Only
$701M upfront
Infectious Disease · Phase 3 · US Only
$2.0B upfront
Infectious Disease · Approved · US Only
$49M upfront
Oncology · Phase 1 · US Only
$42M upfront
Neurology/CNS · Phase 1 · US Only
$90M upfront
Immunology · Phase 1 · US Only
$126M upfront
Metabolic/Obesity · Phase 1 · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Infectious Disease Phase 1 Deal Benchmarks — US Only (2026). Retrieved from https://solidus.ambrosiaventures.co/data/infectious-disease-phase-1-deals-us
<a href="https://solidus.ambrosiaventures.co/data/infectious-disease-phase-1-deals-us">Infectious Disease Phase 1 Deal Benchmarks — US Only (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=infectiousDisease&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.